CMPS - How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space
(NewsDirect)
By Faith Ashmore, Benzinga
Artificial Intelligence (AI) is rapidlypenetrating a number of different sectors, including healthcare. Theuse of AI in mental health has opened up the possibility of newavenues of care, potentially allowing for more efficient diagnosis,treatment and patient care. Machine learning algorithms can analyzevast amounts of data – including patient medical records, geneticinformation and environmental factors – to potentially identifypatterns and predict disorders. Clinicians can also benefit from moreaccurate and timely diagnoses based on objective digitalsignals.
COMPASS Pathways (NASDAQ:CMPS) is currently developing AI-informed digital systems to assist aninvestigational treatment for mental health conditions, includingtreatment-resistant depression (TRD), anorexia nervosa andpost–traumatic stress disorder (PTSD). The company is best known forits investigational psilocybin treatment and its R&D focus onmental health conditions. Its goal is to develop new and moreeffective treatment options for individuals with treatment-resistantdepression and other difficult-to-treat mental healthconditions.
The company’sinnovative approach has already yielded promising results, and theyreceived FDA Breakthrough Therapy designation in the U.S. andInnovative Licensing and Access Pathway designation in the U.K. fortheir investigational COMP360 psilocybin treatment. In late 2021,COMPASS Pathways announced the completion of a randomized, controlleddouble-blind phase 2b study of COMP360 psilocybin treatment involving233 patients with TRD in 22 sites across Europe and North America.However, the company believes that drug innovation alone is not enoughto improve mental health care.
Inaddition to COMP360 and to better support the drug, COMPASS Pathwayshas developed three digital tools to help support patients andtherapists to ensure the best possible treatment. While these toolswill be used in tandem with the COMP360 treatment, the tools werebuilt to be scalable and revolutionize the treatment of mental healthdisorders.
Therapist COMPanion is aweb-based portal that supports therapists through all phases ofpatient care. Psilocybin administration is relatively new to providersso Therapist COMPanion acts as a tool for the provider to ensure thattreatment is conducted in the right way.
myPathfinder is a patient-facing app that provides guidancethroughout COMP360. The psilocybin treatment is grouped into threephases: preparation, administration and integration. COMPASS Pathwayswas built on the belief that patients deserve better care, especiallypatients who have been underserved and felt overlooked by the systemafter being diagnosed as treatment-resistant. This platform is anessential component of taking better care of the patient and ensuringthey have the tools to understand their treatment and psilocybinexperience.
However, the company’smost expansive digital tool is Chanterelle, an AI and analyticsinfrastructure that can be used for continuous optimization throughouttreatment, as well as data collection to help expand a deeperunderstanding of treatment-resistant disorders. The program recordssessions with the patients, with their consent, and can glean a betterunderstanding of success rates using AI and natural languageprocessing. Chanterelle uses the BART large language model whichdenotes the valence and arousal of the participant and therapist toassess the emotional tenor of the conversation and to betterunderstand if treatment is succeeding.
Chanterelle’s application could go beyond COMP360 and wasdesigned to be scalable. The company is working to provide a moreconcrete and evidence-based way of measuring the success of treatment.While COMPASS Pathways is not the only mental healthcare company tobridge the gap between AI and care, the company’s ability to designplatforms that can be used for a variety of disorders sets it apartfrom competitors like MindMed and Medtronic.
Featured photo by Steve Johnson on Unsplash
CompanyBioCOMPASS Pathways plc (Nasdaq: CMPS) is a mental health care companydedicated to accelerating patient access to evidence-based innovationin mental health. Our focus is on improving the lives of those who aresuffering with mental health challenges and who are not helped bycurrent treatments. We are pioneering the development of a new modelof psilocybin therapy, in which our proprietary formulation ofsynthetic psilocybin, COMP360, is administered in conjunction withpsychological support. COMP360 has been designated a BreakthroughTherapy by the U.S. Food and Drug Administration (FDA) and hasreceived Innovative Licensing and Access Pathway (ILAP) designation inthe UK for treatment-resistant depression (TRD). We have commenced aphase 3 clinical program of COMP 360 psilocybin therapy in TRD, thelargest randomised, controlled, double-blind psilocybin therapyclinical program ever conducted. Previously, we completed a phase 2bstudy with top line data showing a statistically significant(p<0.001) and clinically relevant improvement in depressive symptomseverity after three weeks for patients who received a single highdose of COMP360 psilocybin with psychological support. We are alsoconducting phase 2 clinical studies of COMP360 psilocybin therapy forpost-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS isheadquartered in London, UK, with offices in New York and SanFrancisco in the United States. Our vision is a world of mentalwellbeing.
This post contains sponsored content. Thiscontent is for informational purposes only and not intended to beinvesting advice.
Contact Details
StephenSchultz
stephen.schultz@compasspathways.com
Copyright (c) 2023 TheNewswire - All rights reserved.